Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Viking Therapeutics Inc.

    NASDAQ: VKTX · Real-Time Price · USD
    26.32
    -0.64 (-2.37%)
    At close: Jun 17, 2025, 3:24 PM

    Viking Therapeutics Statistics

    Share Statistics

    Viking Therapeutics has 112.31M shares outstanding. The number of shares has increased by 1.8% in one year.

    Shares Outstanding

    n/a
    		 112.31M

    Shares Change (YoY)

    n/a
    		 1.8%

    Shares Change (QoQ)

    n/a
    		 0.73%

    Owned by Institutions (%)

    n/a
    		 73.95%

    Shares Floating

    n/a
    		 108.99M

    Failed to Deliver (FTD) Shares

    n/a
    		 36,849

    FTD / Avg. Volume

    n/a
    		 0.99%

    Short Selling Information

    The latest short interest is 26.71M, so 23.78% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 26.71M

    Short % of Shares Out

    n/a
    		 23.78%

    Short % of Float

    n/a
    		 28.54%

    Short Ratio (days to cover)

    n/a
    		 10.73

    Valuation Ratios

    The PE ratio is -39.9 and the forward PE ratio is -10.17. Viking Therapeutics's PEG ratio is -3.63.

    PE Ratio

    n/a
    		 -39.9

    Forward PE

    n/a
    		 -10.17

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 3.9

    PB Ratio

    n/a
    		 4.98

    P/FCF Ratio

    n/a
    		 -49.98

    PEG Ratio

    n/a
    		 -3.63
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Viking Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 33.09, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 33.09

    Quick Ratio

    n/a
    		 33.09

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 -0.01

    Debt / FCF

    n/a
    		 -0.01

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-2,443,622.22

    Employee Count

    n/a
    		 45

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -48.19% in the last 52 weeks. The beta is 0.64, so Viking Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.64

    52-Week Price Change

    n/a
    		 -48.19%

    50-Day Moving Average

    n/a
    		 26.39

    200-Day Moving Average

    n/a
    		 41.82

    Relative Strength Index (RSI)

    n/a
    		 48.08

    Average Volume (20 Days)

    n/a
    		 3,725,871

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -150.92M

    Net Income

    n/a
    		 -109.96M

    EBITDA

    n/a
    		 -109.52M

    EBIT

    n/a
    		 n/a

    Earnings Per Share (EPS)

    n/a
    		 -1.01
    Full Income Statement

    Balance Sheet

    The company has 26.68M in cash and 1.12M in debt, giving a net cash position of 25.56M.

    Cash & Cash Equivalents

    n/a
    		 26.68M

    Total Debt

    n/a
    		 1.12M

    Net Cash

    n/a
    		 25.56M

    Retained Earnings

    n/a
    		 -487.91M

    Total Assets

    n/a
    		 866.99M

    Working Capital

    n/a
    		 846.45M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -87.79M and capital expenditures 0, giving a free cash flow of -87.79M.

    Operating Cash Flow

    n/a
    		 -87.79M

    Capital Expenditures

    n/a
    		 n/a

    Free Cash Flow

    n/a
    		 -87.79M

    FCF Per Share

    n/a
    		 -0.81
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    VKTX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for VKTX is $96, which is 256.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $96

    Price Target Difference

    n/a
    		 256.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 13
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 94.18

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist